Table 7. Stratified event-free survival analysis of rs rs7200690, rs7198799 in CDH1 and rs4533622 in CTNNB1 by clinical stage.
| Noevent /No (%) | ||||||
|---|---|---|---|---|---|---|
| Clinical stage | rs7200690 CC/CT | rs7200690 TT | HR (95%CI) | P | aHR (95%CI) * | P * |
| 0-I | 8/126 (6) | 3/11 (27) | 5.05 (1.32–19.27) | 0.0179 | 10.30 (1.42–74.73) | 0.0211 |
| II-IV | 109/578 (19) | 9/40 (23) | 1.33 (0.67–2.63) | 0.4112 | 1.37 (1.68–2.70) | 0.2111 |
| Clinical stage | rs7198799 CC/CT | rs7198799 TT | ||||
| 0-I | 9/132 (7) | 2/5 (40) | 5.97 (1.29–27.70) | 0.0226 | 10.91 (1.13–105.34) | 0.0389 |
| II-IV | 115/595 (19) | 3/23 (13) | 0.71 (0.23–2.24) | 0.5622 | 0.80 (0.26–2.29) | 0.4322 |
| Clinical stage | rs4533622 CC/CA | rs4533622 AA | ||||
| 0-I | 9/131 (7) | 2/6 (33) | 4.84 (1.03–22.70) | 0.0456 | 9.04 (0.93–87.96) | 0.0580 |
| II-IV | 113/574 (20) | 5/44 (11) | 0.59 (0.24–1.45) | 0.2530 | 1.02 (0.37–2.82) | 0.9721 |
* Adjusted for ER status, PR status, Her2 status, tumor size, clinical stage, lymphnode metastasis, chemotherapy and endocrine therapy.
Bold numbers indicate a statistical significance at 0.05 level.